Dr. Rosmarin is the Chair of the Department of Dermatology at Indiana University and a clinical investigator. He previously served as Vice-Chair for Research and Education at Tufts Medical Center focusing on clinical trials for inflammatory disorders of the skin. For his training, Dr. Rosmarin went to medical school at NYU, dermatology residency at Boston University-Tufts Combined training program, and fellowship at Brigham and Women’s Hospital. Dr. Rosmarin joined Tufts Medical Center in 2013 focusing as a clinical trial investigator. In 2016, Dr. Rosmarin became the Director of the Clinical Trials Unit in the Department of Dermatology at Tufts Medical Center. Dr. Rosmarin’s studies have resulted in him becoming the PI for multicentered trials evaluating topical ruxolitinib in vitiligo, which has led to the first ever FDA indication for repigmenting vitiligo. Dr. Rosmarin is the first to use dupilumab for bullous pemphigoid which is now in a phase 3 program for an indication. Clinically Dr. Rosmarin is nationally recognized and serves as a referral for physicians with difficult to manage inflammatory diseases such as atopic dermatitis.
Subscribe to our newsletter for updates delivered straight to you